Moderna has signed a ten-year agreement with Lonza for large-scale manufacture of its vaccine candidate, mRNA-1273, against Covid-19 and other products in the future.
Under the deal, the companies will create manufacturing suites at Lonza’s facilities in the US and Switzerland to produce mRNA-1273.
With technology transfer scheduled to start next month, the partners plan to manufacture the first batches of the Covid-19 vaccine candidate at Lonza’s US sites in July.
The aim is to gradually establish production suites across Lonza facilities globally to enable the manufacture of material equivalent to up to one billion doses of the vaccine per year.